Skip to content
value.today
AcelRx Pharmaceuticals Inc. logo

AcelRx Pharmaceuticals Inc.

Formerly Surx, Inc.

Total raised
$44 M
3 rounds on record
Latest round
$21 M
Jun 2011
First round on record
Nov 2009
Today
Went public
See the company page

AcelRx Pharmaceuticals Inc. is listed today as Talphera, Inc.: market value, financials and filings are on its company page.

Funding rounds

3 counted as startup funding, 6 other private sales on record. Open the number of investors for the round's details.

Funding rounds of AcelRx Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2025$17 MPrivate placement after listing$10 to $50 million

AcelRx Pharmaceuticals Inc.: Private sale, Sep 2025

Investors in this round

13 investors had bought by the notice of Sep 15, 2025: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for AcelRx Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$17 M of $29 M offered; $12 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Badri P Dasu · Executive Officer
  • Raffi P Asadorian · Executive Officer
  • Shakil P Aslam · Executive Officer
  • Vincent J Angotti · Executive Officer, Director
  • Abhinav J Jain · Director
  • Adrian P Adams · Director
  • Jill P Broadfoot · Director
  • Marina P Bozilenko · Director
  • Mark J Wan · Director
  • Stephen J Hoffman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Raffi Asadorian, Chief Financial Officer. Source: SEC Form D, newest notice filed Sep 15, 2025. Read the notice at the SEC.

equity, optionsSEC
Apr 2025$5 MPrivate placement after listing$2 to $10 million

AcelRx Pharmaceuticals Inc.: Private sale, Apr 2025

Investors in this round

11 investors had bought by the notice of Apr 17, 2025: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for AcelRx Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $15 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
$1,050,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Badri P Dasu · Executive Officer
  • Raffi P Asadorian · Executive Officer
  • Shakil P Aslam · Executive Officer
  • Vincent J Angotti · Executive Officer, Director
  • Abhinav J Jain · Director
  • Adrian P Adams · Director
  • Jill P Broadfoot · Director
  • Marina P Bozilenko · Director
  • Mark J Wan · Director
  • Stephen J Hoffman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • A.G.P./Alliance Global Partners (CRD 8361) · New York, New YorkSold in all US states
  • BTIG, LLC (CRD 122225) · San Francisco, CaliforniaSold in all US states

Signed by Raffi Asadorian, Chief Financial Officer. Source: SEC Form D, newest notice filed Apr 17, 2025. Read the notice at the SEC.

equity, optionsSEC
Jan 2024$6 MPrivate placement after listing$2 to $10 million

AcelRx Pharmaceuticals Inc.: Private sale, Jan 2024

Investors in this round

6 investors had bought by the notice of Jan 29, 2024: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for AcelRx Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and finders' fees and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Badri B Dasu · Executive Officer
  • Pamela P Palmer · Executive Officer, Director
  • Raffi P Asadorian · Executive Officer
  • Vincent J Angotti · Executive Officer, Director
  • Abhinav B Jain · Director
  • Adrian P Adams · Director
  • Howard B Rosen · Director
  • Jill P Broadfoot · Director
  • Marina P Bozilenko · Director
  • Mark B Wan · Director
  • Richard P Afable · Director
  • Stephen J Hoffman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Raffi Asadorian, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 29, 2024. Read the notice at the SEC.

optionsSEC
Jul 2023$10 MPrivate placement after listing$10 to $50 million

AcelRx Pharmaceuticals Inc.: Private sale, Jul 2023

Investors in this round

10 investors had bought by the notice of Jul 28, 2023: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for AcelRx Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$625,001
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Raffi P. Asadorian · Executive Officer
  • Vincent J. Angotti · Executive Officer, Director
  • Adrian P. Adams · Director
  • Howard B. Rosen · Director
  • Jill P. Broadfoot · Director
  • Marina P. Bozilenko · Director
  • Mark B. Wan · Director
  • Pamela P. Palmer · Director
  • Richard P. Afable · Director
  • Stephen J. Hoffman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in CT, IL, NC, NV, NY, and outside the US

Signed by Raffi Asadorian, Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 28, 2023. Read the notice at the SEC.

equity, optionsSEC
Jan 2022$5 MPrivate placement after listing$2 to $10 million

AcelRx Pharmaceuticals Inc.: Private sale, Jan 2022

Investors in this round

32 investors had bought by the notice of Jan 24, 2022: 28 accredited, 4 not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for AcelRx Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $6 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Badri Dasu · Executive Officer
  • Pamela Palmer · Executive Officer, Director
  • Raffi Asadorian · Executive Officer
  • Vincent Angotti · Executive Officer, Director
  • Adrian Adams · Director
  • Howard Rosen · Director
  • Jill Broadfoot · Director
  • Marina Bozilenko · Director
  • Mark Edwards · Director
  • Mark Wan · Director
  • Richard Afable · Director
  • Stephen Hoffman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Raffi Asadorian, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 24, 2022. Read the notice at the SEC.

equitySEC
Jun 2012$10 MPrivate placement after listing$10 to $50 million

AcelRx Pharmaceuticals Inc.: Private sale, Jun 2012

Investors in this round

10 investors had bought by the notice of Jun 7, 2012: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for AcelRx Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$625,000
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks finders' fees as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Anil Dasu · Executive Officer
  • James Welch · Executive Officer
  • Larry Hamel · Executive Officer
  • Pamela Palmer · Executive Officer, Director
  • Richard King · Executive Officer, Director
  • Guy Nohra · Director
  • Howie Rosen · Director
  • Mark Edwards · Director
  • Mark Wan · Director
  • Stephen Hoffman · Director
  • Thomas Schreck · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Common Stock; Warrants to purchase Common Stock; Common Stock issuable upon exercise of Warrants”
  • On the use of proceeds: “The proceeds will be used for general corporate purposes.”

Signed by Mark B. Weeks, Secretary. Source: SEC Form D, newest notice filed Jun 7, 2012. Read the notice at the SEC.

equity, optionsSEC
Jun 2011$21 MNo. 3$10 to $50 million

AcelRx Pharmaceuticals Inc.: Raise no. 3, Jun 2011

Investors in this round

2 investors had bought by the notice of Jul 13, 2011: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for AcelRx Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$21 M of $21 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Badri N. Dasu · Executive Officer
  • Hamel G. Lawrence · Executive Officer
  • James H. Welch · Executive Officer
  • Pamela P. Palmer · Executive Officer
  • Richard King · Executive Officer, Director
  • Guy J. Nohra · Director
  • Howard B. Rosen · Director
  • Mark B. Wan · Director
  • Stephen J. Hoffman · Director
  • Thomas H. Schreck · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Promissory Notes in which $3,000,000 dollars of which can be converted into Company Common Stock at a fixed conversion price of $5.73; Warrants to purchase Common Stock and Common Stock issuable upon exercise of Warrants and conversion of Promissory Notes”
  • On the use of proceeds: “Proceeds will be used for the ARX-01 Phase 3 clinical trial in addition to the general business purposes.”

Signed by James H. Welch, Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 13, 2011. Read the notice at the SEC.

debt, optionsSEC
Sep 2010$8 MNo. 2$2 to $10 million

AcelRx Pharmaceuticals Inc.: Raise no. 2, Sep 2010

Investors in this round

8 investors had bought by the notice of Sep 21, 2010: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for AcelRx Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $12 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Anil Dasu · Executive Officer
  • Carter King · Executive Officer
  • Larry Hamel · Executive Officer
  • Linda Judge · Executive Officer
  • Pamela Palmer · Executive Officer, Director
  • Richard King · Executive Officer, Director
  • Guy Nohra · Director
  • Howie Rosen · Director
  • Mark Wan · Director
  • Stephen Hoffman · Director
  • Thomas Schreck · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Promissory Notes convertible into Preferred Stock; Warrants to purchase Preferred Stock”
  • On the use of proceeds: “The proceeds will be used for general corporate purposes.”

Signed by Mark B. Weeks, Secretary. Source: SEC Form D, newest notice filed Sep 21, 2010. Read the notice at the SEC.

debt, optionsSEC
Nov 2009$15 MNo. 1$10 to $50 million

AcelRx Pharmaceuticals Inc.: Raise no. 1, Nov 2009

Investors in this round

8 investors had bought by the notice of Nov 25, 2009: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for AcelRx Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$15 M of $30 M offered; $15 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Anil A Dasu · Executive Officer
  • Carter A King · Executive Officer
  • Larry A Hamel · Executive Officer
  • Linda A Judge · Executive Officer
  • Mark B Weeks · Executive Officer
  • Pamela A Palmer · Executive Officer, Director
  • Thomas A Schreck · Executive Officer, Director
  • Guy B Nohra · Director
  • Howie B Rosen · Director
  • Mark B Wan · Director
  • Steve B Sullivan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “The proceeds will be used for general corporate purposes.”

Signed by Mark B. Weeks, Secretary. Source: SEC Form D, newest notice filed Nov 25, 2009. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • AcelRx Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2025).

    SEC Form D · Sep 2025

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Sep 2025

That is all the official record says: AcelRx Pharmaceuticals Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of AcelRx Pharmaceuticals Inc. are on record.

Investors#

11 named in official filings. Open an investor to see everything it has backed.

Investors in AcelRx Pharmaceuticals Inc.
InvestorKindAmountRoundRoleSource
Acmp IV LLCOthernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Acp IV, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Skyline Venture Management IV, LLCVenture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Skyline Venture Partners Qualified Purchaser Fund IV L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Thomas A. SchreckPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2011)SEC Form 3
Three Arch Associates III LPFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Three Arch Associates IV LPFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Three Arch Management III LLCFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Three Arch Management IV, L.L.C.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Three Arch Partners III LPFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Three Arch Partners IV LPFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2011)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 8 investors.

Largest shareholders today

Institutions holding Talphera, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by AcelRx Pharmaceuticals Inc.
NameRoleNamed in
Badri P DasuExecutive officerSep 2025
Raffi P AsadorianExecutive officerSep 2025
Shakil P AslamExecutive officerSep 2025
Vincent J AngottiExecutive officerSep 2025
Badri B DasuExecutive officerJan 2024
Pamela P PalmerExecutive officerJan 2024
Raffi P. AsadorianExecutive officerJul 2023
Vincent J. AngottiExecutive officerJul 2023
Badri DasuExecutive officerJan 2022
Pamela PalmerExecutive officerJan 2022
Raffi AsadorianExecutive officerJan 2022
Vincent AngottiExecutive officerJan 2022
Anil DasuExecutive officerJun 2012
James WelchExecutive officerJun 2012
Larry HamelExecutive officerJun 2012
Richard KingExecutive officerJun 2012
Badri N. DasuExecutive officerJul 2011
Hamel G. LawrenceExecutive officerJul 2011
James H. WelchExecutive officerJul 2011
Pamela P. PalmerExecutive officerJul 2011
Carter KingExecutive officerSep 2010
Linda JudgeExecutive officerSep 2010
Anil A DasuExecutive officerNov 2009
Carter A KingExecutive officerNov 2009
Larry A HamelExecutive officerNov 2009
Linda A JudgeExecutive officerNov 2009
Mark B WeeksExecutive officerNov 2009
Pamela A PalmerExecutive officerNov 2009
Thomas A SchreckExecutive officerNov 2009
Abhinav J JainDirectorSep 2025
Adrian P AdamsDirectorSep 2025
Jill P BroadfootDirectorSep 2025
Marina P BozilenkoDirectorSep 2025
Mark J WanDirectorSep 2025
Stephen J HoffmanDirectorSep 2025
Vincent J AngottiDirectorSep 2025
Abhinav B JainDirectorJan 2024
Howard B RosenDirectorJan 2024
Mark B WanDirectorJan 2024
Pamela P PalmerDirectorJan 2024

About

Company in Redwood City, United States.

Went public since 2011. Its SEC number is that of a company listed on a stock exchange.